Amedeo Smart

Free Medical Literature Service


 

Amedeo

Multiple Sclerosis

  Free Subscription

Articles published in
J Neurol Sci
    August 2021
  1. RICE DR, Kaplan TB, Hotan GC, Vogel AC, et al
    Electronic pill bottles to monitor and promote medication adherence for people with multiple sclerosis: A randomized, virtual clinical trial.
    J Neurol Sci. 2021;428:117612.
    >> Share

    July 2021
  2. VISSER LA, Huls SPI, Uyl-de Groot CA, de Bekker-Grob EW, et al
    An implantable device to treat multiple sclerosis: A discrete choice experiment on patient preferences in three European countries.
    J Neurol Sci. 2021;428:117587.
    >> Share

    June 2021
  3. VAN DER HIELE K, van Gorp DAM, van Egmond EEA, Jongen PJ, et al
    Self-reported occupational functioning in persons with relapsing-remitting multiple sclerosis: Does personality matter?
    J Neurol Sci. 2021;427:117561.
    >> Share

  4. JAKIMOVSKI D, Zivadinov R, Vaughn CB, Ozel O, et al
    Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis.
    J Neurol Sci. 2021;427:117552.
    >> Share

  5. WIJERATNE T, Grisold W, Carroll W
    World Brain Day 2021 campaign continue to gain the momentum; join us to stop multiple sclerosis.
    J Neurol Sci. 2021;427:117547.
    >> Share

  6. FUJIMORI J, Nakashima I
    Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis.
    J Neurol Sci. 2021;427:117528.
    >> Share

    May 2021
  7. TAZZA F, Lapucci C, Cellerino M, Boffa G, et al
    Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
    J Neurol Sci. 2021;427:117501.
    >> Share

  8. DE MERCANTI SF, Signori A, Cordioli C, Signoriello E, et al
    MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
    J Neurol Sci. 2021;424:117385.
    >> Share

    April 2021
  9. YOUNG CA, Mills R, Rog D, Sharrack B, et al
    Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy.
    J Neurol Sci. 2021;426:117437.
    >> Share

  10. ALLUM JHJ, Rust HM, Lutz N, Schouenborg C, et al
    Characteristics of improvements in balance control using vibro-tactile biofeedback of trunk sway for multiple sclerosis patients.
    J Neurol Sci. 2021;425:117432.
    >> Share

    March 2021
  11. FERRARO D, Annovazzi P, Lanzillo R, Calabrese M, et al
    A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia.
    J Neurol Sci. 2021;424:117430.
    >> Share

    February 2021
  12. EILAM-STOCK T, Shaw MT, Krupp LB, Charvet LE, et al
    Early neuropsychological markers of cognitive involvement in multiple sclerosis.
    J Neurol Sci. 2021;423:117349.
    >> Share

    January 2021
  13. BOSE G, Freedman MS
    Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis.
    J Neurol Sci. 2021;421:117324.
    >> Share

  14. KOVVURU S, Nalleballe K, Onteddu SR, Sharma R, et al
    Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic.
    J Neurol Sci. 2021;420:117230.
    >> Share

    December 2020
  15. WEBER J, Bernsdorff N, Robinson T, Endres D, et al
    Diagnosis of multiple sclerosis in times of MOG and AQP4 autoantibody testing - A monocentric study.
    J Neurol Sci. 2020;421:117289.
    >> Share

    October 2020
  16. VARMA-DOYLE AV, Lukiw WJ, Zhao Y, Lovera J, et al
    A hypothesis-generating scoping review of miRs identified in both multiple sclerosis and dementia, their protein targets, and miR signaling pathways.
    J Neurol Sci. 2020 Oct 23:117202. doi: 10.1016/j.jns.2020.117202.
    >> Share

  17. BARREIRO-GONZALEZ A, Sanz MT, Carratala-Bosca S, Perez-Miralles F, et al
    Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks.
    J Neurol Sci. 2020;419:117180.
    >> Share

    September 2020
  18. ILARDI M, Nolan-Kenney R, Fatterpekar G, Hasanaj L, et al
    Role for OCT in detecting hemi-macular ganglion cell layer thinning in patients with multiple sclerosis and related demyelinating diseases.
    J Neurol Sci. 2020;419:117159.
    >> Share

  19. CHAUDHRY F, Bulka H, Rathnam AS, Said OM, et al
    COVID-19 in multiple sclerosis patients and risk factors for severe infection.
    J Neurol Sci. 2020;418:117147.
    >> Share

  20. JAKIMOVSKI D, Zivadinov R, Dwyer MG, Bergsland N, et al
    High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis.
    J Neurol Sci. 2020;418:117120.
    >> Share

    August 2020
  21. GELIBTER S, Orrico M, Moiola L, Dagna L, et al
    Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis.
    J Neurol Sci. 2020;418:117104.
    >> Share

  22. SHAH Z, Wasay M, Chaudhry BZ, Fredrikson S, et al
    Multiple sclerosis in Pakistan: Current status and future perspective.
    J Neurol Sci. 2020;418:117066.
    >> Share

    July 2020
  23. MINACAPELLI E, Giordano A, Falautano M, Sangalli F, et al
    Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios.
    J Neurol Sci. 2020;417:117064.
    >> Share

  24. HUGHES AJ, Patel K, Fitzgerald KC, Brown A, et al
    Reliability and validity of the multiple sclerosis resiliency scale (MSRS).
    J Neurol Sci. 2020;418:116983.
    >> Share

  25. LUCA B, Tommaso G, Bavaro DF, Laura M, et al
    Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
    J Neurol Sci. 2020;416:117011.
    >> Share

    June 2020
  26. ABBOUD H, Serra A
    The pressing questions in multiple sclerosis Care in the era of COVID-19.
    J Neurol Sci. 2020;416:117005.
    >> Share

  27. PROCKL V, Nickel FT, Utz KS, Frohlich K, et al
    Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients.
    J Neurol Sci. 2020;415:116973.
    >> Share

  28. WELLER D, Lorincz L, Sutter T, Reuter K, et al
    Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis.
    J Neurol Sci. 2020;416:116978.
    >> Share

    May 2020
  29. LAMARGUE D, Koubiyr I, Deloire M, Saubusse A, et al
    Effect of cognitive rehabilitation on neuropsychological and semiecological testing and on daily cognitive functioning in multiple sclerosis: The REACTIV randomized controlled study.
    J Neurol Sci. 2020;415:116929.
    >> Share

  30. KIM H, Lim YM, Kim G, Lee EJ, et al
    Choroid plexus changes on magnetic resonance imaging in multiple sclerosis and neuromyelitis optica spectrum disorder.
    J Neurol Sci. 2020;415:116904.
    >> Share

  31. AHMED SI, Lohana N, Javed G, Bareeqa SB, et al
    Semantic fluency and cognitive function impairment in multiple sclerosis patients.
    J Neurol Sci. 2020;415:116898.
    >> Share

    April 2020
  32. FALSAFI Z, Tafakhori A, Agah E, Mojarrad M, et al
    Safety and efficacy of memantine for multiple sclerosis-related fatigue: A pilot randomized, double-blind placebo-controlled trial.
    J Neurol Sci. 2020;414:116844.
    >> Share

  33. TSANTES E, Curti E, Collura F, Bazzurri V, et al
    Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2020;414:116827.
    >> Share

    March 2020
  34. CUELLO JP, Martinez Gines ML, Tejeda-Velarde A, Medina Heras S, et al
    Cytokine profile during pregnancy predicts relapses during pregnancy and postpartum in multiple sclerosis.
    J Neurol Sci. 2020;414:116811.
    >> Share

  35. RUSSO C, Cocozza S, Riccio E, Pontillo G, et al
    Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study.
    J Neurol Sci. 2020;412:116782.
    >> Share

  36. SCOTT TF, Bertha N
    The impact of multiple sclerosis relapses on worsening over the long term; insights in the treatment era.
    J Neurol Sci. 2020;413:116773.
    >> Share

  37. FUKUMOTO S, Nakamura Y, Watanabe M, Isobe N, et al
    Risk HLA-DRB1 alleles differentially influence brain and lesion volumes in Japanese patients with multiple sclerosis.
    J Neurol Sci. 2020;413:116768.
    >> Share

    February 2020
  38. OUALLET JC, Radat F, Creange A, Abdellaoui M, et al
    Evaluation of emotional disorders before and during treatment with interferon beta in patients with multiple sclerosis.
    J Neurol Sci. 2020;413:116739.
    >> Share

  39. SOLARO C, Cattaneo D, Basteris A, Carpinella I, et al
    Haptic vs sensorimotor training in the treatment of upper limb dysfunction in multiple sclerosis: A multi-center, randomised controlled trial.
    J Neurol Sci. 2020;412:116743.
    >> Share

  40. RINI AM, Clerici VT, Rinaldi E, Modesto M, et al
    Severe thrombocytopenia during Natalizumab therapy: A case report.
    J Neurol Sci. 2020;409:116587.
    >> Share

    January 2020
  41. MARTINEZ-LAPISCINA EH, Mahatanan R, Lee CH, Charoenpong P, et al
    Associations of serum 25(OH) vitamin D levels with clinical and radiological outcomes in multiple sclerosis, a systematic review and meta-analysis.
    J Neurol Sci. 2020;411:116668.
    >> Share

    December 2019
  42. GROMISCH ES, Foley FW
    Can semantic fluency be used as an alternative or additional measure in the abbreviated Minimal Assessment of Cognitive Function in Multiple Sclerosis (aMACFIMS)?
    J Neurol Sci. 2019;410:116640.
    >> Share

  43. DE CARVALHO JENNINGS PEREIRA W, Flauzino T, Alfieri DF, Oliveira SR, et al
    Immune-inflammatory, metabolic and hormonal biomarkers are associated with the clinical forms and disability progression in patients with multiple sclerosis: A follow-up study.
    J Neurol Sci. 2019;410:116630.
    >> Share

  44. FUJII T, Yamasaki R, Miyachi Y, Nagata S, et al
    Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis.
    J Neurol Sci. 2019;409:116619.
    >> Share

  45. CRISTIANO E, Rojas JI, Alonso R, Alvez Pinheiro A, et al
    Consensus recommendations on the management of multiple sclerosis patients in Argentina.
    J Neurol Sci. 2019;409:116609.
    >> Share

    November 2019
  46. ZANETTA C, Robotti M, Nozzolillo A, Sangalli F, et al
    Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature.
    J Neurol Sci. 2019;409:116603.
    >> Share

    October 2019
  47. UYGUR M, de Freitas PB, Barone DA
    Rate of force development and relaxation scaling factors are highly sensitive to detect upper extremity motor impairments in multiple sclerosis.
    J Neurol Sci. 2019;408:116500.
    >> Share

  48. CEDERBERG KLJ, Jeng B, Sasaki JE, Braley TJ, et al
    Physical activity, sedentary behavior, and restless legs syndrome in persons with multiple sclerosis.
    J Neurol Sci. 2019;407:116531.
    >> Share

    September 2019
  49. SRIWASTAVA S, Yarraguntla K, Zutshi D, Basha MM, et al
    Relevance of cerebrospinal fluid findings in patients with multiple sclerosis and seizures.
    J Neurol Sci. 2019;406:116482.
    >> Share

  50. O'HERLIHY F, John NA, Li V, Porter B, et al
    Screening for urinary tract colonisation prior to corticosteroid administration in acute multiple sclerosis relapses: Validation of an updated algorithm.
    J Neurol Sci. 2019;407:116456.
    >> Share

  51. HNILICOVA P, Kantorova E, Polacek H, Grendar M, et al
    Altered hypothalamic metabolism in early multiple sclerosis - MR spectroscopy study.
    J Neurol Sci. 2019;407:116458.
    >> Share

    August 2019
  52. NOHARA S, Ishii A, Yamamoto F, Yanagiha K, et al
    GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis.
    J Neurol Sci. 2019;405:116429.
    >> Share

  53. SA M, Nunes CC, da Silva AM, Mota P, et al
    JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results.
    J Neurol Sci. 2019;406:116426.
    >> Share

  54. VANOLI E, Montano N, De Angelis G, Badilini F, et al
    Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod.
    J Neurol Sci. 2019;405:116423.
    >> Share

    July 2019
  55. BATCHELLER L, Baker D
    Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?
    J Neurol Sci. 2019;404:19-28.
    >> Share

    June 2019
  56. MUCCILLI A, Nehme A, Labrie M, Girard M, et al
    Varicella-zoster virus vasculopathy in a multiple sclerosis patient on fingolimod.
    J Neurol Sci. 2019;403:119-121.
    >> Share

  57. SEDEEQ MS, El-Nahrery EMA, Shalaby N, Hussein M, et al
    Micro-RNA-96 and interleukin-10 are independent biomarkers for multiple sclerosis activity.
    J Neurol Sci. 2019;403:92-96.
    >> Share

  58. MINAGAR A, Alexander JS
    Cervical spinal cord atrophy impact on quality of life in MS: A neuroimaging study.
    J Neurol Sci. 2019;401:101-102.
    >> Share

  59. MASUDA H, Mori M, Hirano S, Kojima K, et al
    Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis.
    J Neurol Sci. 2019;403:78-84.
    >> Share

    May 2019
  60. DE ROQUEMAUREL A, Galli P, Landais A, Avendano S, et al
    Fingolimod for the treatment of multiple sclerosis in French West Indies, a real-world study in patients from African ancestry.
    J Neurol Sci. 2019;402:180-187.
    >> Share

    April 2019
  61. ZURAWSKI J, Glanz BI, Healy BC, Tauhid S, et al
    The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis.
    J Neurol Sci. 2019;403:38-43.
    >> Share

    March 2019
  62. BOZIKI M, Lagoudaki R, Melo P, Kanidou F, et al
    Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
    J Neurol Sci. 2019;401:43-50.
    >> Share

  63. BEIER M, Hughes AJ, Williams MW, Gromisch ES, et al
    Brief and cost-effective tool for assessing verbal learning in multiple sclerosis: Comparison of the Rey Auditory Verbal Learning Test (RAVLT) to the California Verbal Learning Test - II (CVLT-II).
    J Neurol Sci. 2019;400:104-109.
    >> Share

    February 2019
  64. KAPLAN TB, Bove R, Galetta K, Healy B, et al
    Effect of pregnancy loss on MS disease activity.
    J Neurol Sci. 2019;397:58-60.
    >> Share

  65. BEH SC
    The "eye of the tiger" in a patient with multiple sclerosis.
    J Neurol Sci. 2019;399:1-2.
    >> Share

    January 2019
  66. FOX E, Vieira MC, Johnson K, Peeples M, et al
    Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3years: a retrospective US claims database analysis.
    J Neurol Sci. 2019;398:163-170.
    >> Share

    December 2018
  67. ZACHARZEWSKA-GONDEK A, Pokryszko-Dragan A, Gondek TM, Koltowska A, et al
    Apparent diffusion coefficient measurements in normal appearing white matter may support the differential diagnosis between multiple sclerosis lesions and other white matter hyperintensities.
    J Neurol Sci. 2018;397:24-30.
    >> Share

    November 2018
  68. PENG A, Qiu X, Zhang L, Zhu X, et al
    Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review.
    J Neurol Sci. 2018;396:202-205.
    >> Share

  69. FRITZ NE, Kloos AD, Kegelmeyer DA, Kaur P, et al
    Supplementary motor area connectivity and dual-task walking variability in multiple sclerosis.
    J Neurol Sci. 2018;396:159-164.
    >> Share

  70. MEJIA M, Rodriguez-Leyva I, Cortes-Enriquez F, Chi-Ahumada E, et al
    Low levels of alpha-synuclein in peripheral tissues are related to clinical relapse in relapsing-remitting multiple sclerosis: a pilot cross-sectional study.
    J Neurol Sci. 2018;396:87-93.
    >> Share

    October 2018
  71. ZILIOTTO N, Zivadinov R, Jakimovski D, Baroni M, et al
    Plasma levels of soluble NCAM in multiple sclerosis.
    J Neurol Sci. 2018;396:36-41.
    >> Share

    September 2018
  72. HEALY BC, Glanz BI, Zurawski JD, Mazzola M, et al
    Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.
    J Neurol Sci. 2018;394:127-131.
    >> Share

  73. POLACHINI CRN, Spanevello RM, Schetinger MRC, Morsch VM, et al
    Cholinergic and purinergic systems: A key to multiple sclerosis?
    J Neurol Sci. 2018;392:8-21.
    >> Share

    August 2018
  74. JAKIMOVSKI D, Weinstock-Guttman B, Hagemeier J, Vaughn CB, et al
    Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage.
    J Neurol Sci. 2018;393:128-134.
    >> Share

  75. POKRYSZKO-DRAGAN A, Banaszek A, Nowakowska-Kotas M, Jezowska-Jurczyk K, et al
    Diffusion tensor imaging findings in the multiple sclerosis patients and their relationships to various aspects of disability.
    J Neurol Sci. 2018;391:127-133.
    >> Share

    July 2018
  76. CRISTIANO E, Rojas JI, Abad P, Adoni T, et al
    Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America.
    J Neurol Sci. 2018;393:4-13.
    >> Share

  77. VOLLMER B, Honce JM, Sillau S, Corboy JR, et al
    The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis.
    J Neurol Sci. 2018;390:89-93.
    >> Share

  78. ZHANG Y, Wang L, Jia H, Liao M, et al
    Genetic variants regulate NR1H3 expression and contribute to multiple sclerosis risk.
    J Neurol Sci. 2018;390:162-165.
    >> Share

    June 2018
  79. KHALID F, Healy BC, Dupuy SL, Chu R, et al
    Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis.
    J Neurol Sci. 2018;392:94-99.
    >> Share

  80. GROMISCH ES, Portnoy JG, Foley FW
    Response to screening ability of cognitive function by two measures in patients with multiple sclerosis.
    J Neurol Sci. 2018 Jun 14. pii: S0022-510X(18)30259.
    >> Share

  81. KAWADA T
    Screening ability of cognitive function by two measures in patients with multiple sclerosis.
    J Neurol Sci. 2018 Jun 13. pii: S0022-510X(18)30258.
    >> Share

    May 2018
  82. KADRNOZKOVA L, Vaneckova M, Sobisek L, Benova B, et al
    Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients.
    J Neurol Sci. 2018;388:87-93.
    >> Share

  83. GROMISCH ES, Portnoy JG, Foley FW
    Comparison of the abbreviated minimal assessment of cognitive function in multiple sclerosis (aMACFIMS) and the brief international cognitive assessment for multiple sclerosis (BICAMS).
    J Neurol Sci. 2018;388:70-75.
    >> Share

  84. ZIVADINOV R, Bergsland N, Hagemeier J, Carl E, et al
    Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures.
    J Neurol Sci. 2018;388:175-181.
    >> Share

  85. KANTOR D, Johnson K, Vieira MC, Signorovitch J, et al
    Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2018;388:168-174.
    >> Share

  86. FABIS-PEDRINI MJ, James I, Seewann A, Yau WY, et al
    Natural history of benign multiple sclerosis: Clinical and HLA correlates in a Western Australian cohort.
    J Neurol Sci. 2018;388:12-18.
    >> Share

  87. MANCA R, Sharrack B, Paling D, Wilkinson ID, et al
    Brain connectivity and cognitive processing speed in multiple sclerosis: A systematic review.
    J Neurol Sci. 2018;388:115-127.
    >> Share

    April 2018
  88. DALGAS U, Langeskov-Christensen M, Skjerbaek A, Jensen E, et al
    Is the impact of fatigue related to walking capacity and perceived ability in persons with multiple sclerosis? A multicenter study.
    J Neurol Sci. 2018;387:179-186.
    >> Share

  89. VYVER MV, Beelen R, De Keyser J, Nagels G, et al
    Plasma citrulline levels are increased in patients with multiple sclerosis.
    J Neurol Sci. 2018;387:174-178.
    >> Share

  90. ZIVADINOV R, Bergsland N, Hagemeier J, Tavazzi E, et al
    Effect of switching from glatiramer acetate 20mg/daily to glatiramer acetate 40mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
    J Neurol Sci. 2018;387:152-156.
    >> Share

  91. AKAISHI T, Takahashi T, Nakashima I
    Oligoclonal bands and periventricular lesions in multiple sclerosis will not increase blood-brain barrier permeability.
    J Neurol Sci. 2018;387:129-133.
    >> Share

  92. GRIST JT, Riemer F, McLean MA, Matys T, et al
    Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from (23)Na-MRI.
    J Neurol Sci. 2018;387:111-114.
    >> Share

    March 2018
  93. FENU G, Lorefice L, Arru M, Sechi V, et al
    Cognition in multiple sclerosis: Between cognitive reserve and brain volume.
    J Neurol Sci. 2018;386:19-22.
    >> Share

    February 2018
  94. MORROW SA, Rosehart H, Sener A, Welk B, et al
    Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis.
    J Neurol Sci. 2018;385:39-44.
    >> Share

  95. BUNAI T, Terada T, Kono S, Yokokura M, et al
    Neuroinflammation following disease modifying therapy in multiple sclerosis: A pilot positron emission tomography study.
    J Neurol Sci. 2018;385:30-33.
    >> Share

  96. CRISTIANO E, Alonso R, Alvez Pinheiro A, Bacile EA, et al
    Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients.
    J Neurol Sci. 2018;385:217-224.
    >> Share

  97. PODBIELSKA M, O'Keeffe J, Hogan EL
    Autoimmunity in multiple sclerosis: role of sphingolipids, invariant NKT cells and other immune elements in control of inflammation and neurodegeneration.
    J Neurol Sci. 2018;385:198-214.
    >> Share

  98. CRISTIANO E, Alonso R, Alvez Pinheiro A, Bacile EA, et al
    Corrigendum to "Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients" [J. Neurol. Sci. 385C (2018) 217-224].
    J Neurol Sci. 2018 Feb 12. pii: S0022-510X(18)30061.
    >> Share

    January 2018
  99. BERTSCH-GOUT M, Loeb R, Finch AK, Javed A, et al
    High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status.
    J Neurol Sci. 2018;384:61-66.
    >> Share

    December 2017
  100. DALLA-COSTA G, Radaelli M, Maida S, Sangalli F, et al
    Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice.
    J Neurol Sci. 2017;383:166-168.
    >> Share

  101. LINGENBERG A, Laidet M, Armand S, Herrmann FR, et al
    Gait stability in patients treated by fingolimod: A longitudinal pilot study on 9 patients with multiple sclerosis.
    J Neurol Sci. 2017;383:105-107.
    >> Share

    November 2017
  102. PEREZ-MARTIN MY, Gonzalez-Platas M, Jimenez-Sosa A, Plata-Bello J, et al
    Can fibrinolytic system components explain cognitive impairment in multiple sclerosis?
    J Neurol Sci. 2017;382:66-72.
    >> Share

  103. PLANCHE V, Moisset X, Morello R, Dumont E, et al
    Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    J Neurol Sci. 2017;382:148-154.
    >> Share

  104. LANGESKOV-CHRISTENSEN D, Feys P, Baert I, Riemenschneider M, et al
    Performed and perceived walking ability in relation to the Expanded Disability Status Scale in persons with multiple sclerosis.
    J Neurol Sci. 2017;382:131-136.
    >> Share

    October 2017
  105. YOUSUF F, Dupuy SL, Tauhid S, Chu R, et al
    A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    J Neurol Sci. 2017 Oct 16. pii: S0022-510X(17)34384.
    >> Share

  106. MILLER P, Soundy A
    The pharmacological and non-pharmacological interventions for the management of fatigue related multiple sclerosis.
    J Neurol Sci. 2017;381:41-54.
    >> Share

  107. KARAMI M, Mehrabi F, Allameh A, Pahlevan Kakhki M, et al
    Klotho gene expression decreases in peripheral blood mononuclear cells (PBMCs) of patients with relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2017;381:305-307.
    >> Share

  108. FERREIRA D, Castro P, Videira G, Filipe JP, et al
    Cerebral autoregulation is preserved in multiple sclerosis patients.
    J Neurol Sci. 2017;381:298-304.
    >> Share

  109. CALVI A, De Riz M, Lecchi E, Pietroboni A, et al
    Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
    J Neurol Sci. 2017;381:296-297.
    >> Share

  110. OLIVEIRA SR, Simao ANC, Alfieri DF, Flauzino T, et al
    Vitamin D deficiency is associated with disability and disease progression in multiple sclerosis patients independently of oxidative and nitrosative stress.
    J Neurol Sci. 2017;381:213-219.
    >> Share

  111. CORREALE J
    Follow-on products for treatment of multiple sclerosis in Latin America: An update.
    J Neurol Sci. 2017;381:153-159.
    >> Share

  112. BEIER M, Gromisch ES, Hughes AJ, Alschuler KN, et al
    Proposed cut scores for tests of the Brief International Cognitive Assessment of Multiple Sclerosis (BICAMS).
    J Neurol Sci. 2017;381:110-116.
    >> Share

  113. MCGEE JC, Minagar A
    Assessing the cerebral gray matter volume in response to fingolimod therapy in multiple sclerosis: A more analytic view.
    J Neurol Sci. 2017 Oct 13. pii: S0022-510X(17)34383.
    >> Share

    September 2017
  114. YAMOUT BI, Said M, Hannoun S, Zeineddine M, et al
    Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.
    J Neurol Sci. 2017;380:79-81.
    >> Share

  115. YANG TT, Wang L, Deng XY, Yu G, et al
    Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2017;380:256-261.
    >> Share

  116. GREEKE EE, Chua AS, Healy BC, Rintell DJ, et al
    Depression and fatigue in patients with multiple sclerosis.
    J Neurol Sci. 2017;380:236-241.
    >> Share

  117. IWANOWSKI P, Losy J, Kramer L, Wojcicka M, et al
    CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    J Neurol Sci. 2017;380:22-26.
    >> Share

  118. LAIDET M, Herrmann FR, Armand S, Assal F, et al
    Does fear of falling predict gait variability in multiple sclerosis?
    J Neurol Sci. 2017;380:212-214.
    >> Share

  119. SCARPAZZA C, Prosperini L, Mancinelli CR, De Rossi N, et al
    Corrigendum to "Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?" [J. Neurol. Sci. 378 (2017) 233-237].
    J Neurol Sci. 2017;380:19.
    >> Share

  120. PICELLI A, Vallies G, Chemello E, Castellazzi P, et al
    Is spasticity always the same? An observational study comparing the features of spastic equinus foot in patients with chronic stroke and multiple sclerosis.
    J Neurol Sci. 2017;380:132-136.
    >> Share

    August 2017
  121. SANTORO M, Mirabella M, De Fino C, Bianco A, et al
    Sativex(R) effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.
    J Neurol Sci. 2017;379:298-303.
    >> Share

  122. GAETANI L, Fanelli F, Riccucci I, Eusebi P, et al
    High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline.
    J Neurol Sci. 2017;379:236-240.
    >> Share

  123. KEUNE PM, Young WR, Paraskevopoulos IT, Hansen S, et al
    Measuring standing balance in multiple sclerosis: Further progress towards an automatic and reliable method in clinical practice.
    J Neurol Sci. 2017;379:157-162.
    >> Share

  124. MORSALJAHAN Z, Rafiei A, Valadan R, Abedini M, et al
    Association between interleukin-32 polymorphism and multiple sclerosis.
    J Neurol Sci. 2017;379:144-150.
    >> Share

    July 2017
  125. FARROKHI M, Masoudifar A, Peykanpour F
    Interleukin 17 and 10 in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2017;378:63.
    >> Share

  126. ROLF L, Muris AH, Bol Y, Damoiseaux J, et al
    Vitamin D3 supplementation in multiple sclerosis: Symptoms and biomarkers of depression.
    J Neurol Sci. 2017;378:30-35.
    >> Share

  127. SCARPAZZA C, Prosperini L, Mancinelli CR, De Rossi N, et al
    Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
    J Neurol Sci. 2017;378:233-237.
    >> Share

  128. TAWFIK TZ, Gad AH, Mehaney DA, El Nahrery E, et al
    Concerning the article "Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients".
    J Neurol Sci. 2017;378:152.
    >> Share

    June 2017
  129. AGLIARDI C, Guerini FR, Zanzottera M, Rovaris M, et al
    Indoleamine-2,3-dioxygenase(IDO)2 polymorphisms are not associated with multiple sclerosis in Italians.
    J Neurol Sci. 2017;377:31-34.
    >> Share

  130. CALABRO RS, Russo M, Naro A, De Luca R, et al
    Robotic gait training in multiple sclerosis rehabilitation: Can virtual reality make the difference? Findings from a randomized controlled trial.
    J Neurol Sci. 2017;377:25-30.
    >> Share

  131. TRENTINI A, Castellazzi M, Romani A, Squerzanti M, et al
    Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients.
    J Neurol Sci. 2017;377:133-136.
    >> Share

  132. SMOLDERS J, Rolf L, Damoiseaux J, Hupperts R, et al
    On the ethics of not supplementing low 25-hydroxyvitamin D levels in a controlled study in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2017 Jun 9. pii: S0022-510X(17)30383.
    >> Share

  133. SHUKLA L, Solanki C, Kulkarni Y, Vadlamani N, et al
    Vitamin D supplementation; effects on depressive symptoms in multiple sclerosis.
    J Neurol Sci. 2017 Jun 9. pii: S0022-510X(17)30384.
    >> Share

    May 2017
  134. JORGENSEN M, Dalgas U, Wens I, Hvid LG, et al
    Muscle strength and power in persons with multiple sclerosis - A systematic review and meta-analysis.
    J Neurol Sci. 2017;376:225-241.
    >> Share

  135. HEESEN C, Kleiter I, Meuth SG, Kramer J, et al
    Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients.
    J Neurol Sci. 2017;376:181-190.
    >> Share

  136. BSTEH G, Monz E, Zamarian L, Hagspiel S, et al
    Combined evaluation of personality, risk and coping in MS patients: A step towards individualized treatment choice - The PeRiCoMS-Study I.
    J Neurol Sci. 2017;376:71-75.
    >> Share

  137. WEINSTOCK-GUTTMAN B, Nair KV, Glajch JL, Ganguly TC, et al
    Two decades of glatiramer acetate: From initial discovery to the current development of generics.
    J Neurol Sci. 2017;376:255-259.
    >> Share

    April 2017
  138. BOURNE T, Waltz M, Casper TC, Kavak K, et al
    Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population.
    J Neurol Sci. 2017;375:371-375.
    >> Share

  139. LYSANDROPOULOS AP, Mavroudakis N, Pandolfo M, El Hafsi K, et al
    HLA genotype as a marker of multiple sclerosis prognosis: A pilot study.
    J Neurol Sci. 2017;375:348-354.
    >> Share

  140. NOORI-ZADEH A, Mesbah-Namin SA, Saboor-Yaraghi AA
    Epigenetic and gene expression alterations of FOXP3 in the T cells of EAE mouse model of multiple sclerosis.
    J Neurol Sci. 2017;375:203-208.
    >> Share

  141. RUBEGNI A, Battisti C, Tessa A, Cerase A, et al
    SPG2 mimicking multiple sclerosis in a family identified using next generation sequencing.
    J Neurol Sci. 2017;375:198-202.
    >> Share

  142. HARTL C, Obermeier V, Gerdes LA, Brugel M, et al
    Seasonal variations of 25-OH vitamin D serum levels are associated with clinical disease activity in multiple sclerosis patients.
    J Neurol Sci. 2017;375:160-164.
    >> Share

  143. REEN GK, Silber E, Langdon DW
    Multiple sclerosis patients' understanding and preferences for risks and benefits of disease-modifying drugs: A systematic review.
    J Neurol Sci. 2017;375:107-122.
    >> Share

    February 2017
  144. ZHOU Y, Fang L, Peng L, Qiu W, et al
    TLR9 and its signaling pathway in multiple sclerosis.
    J Neurol Sci. 2017;373:95-99.
    >> Share

  145. WUNDES A, Bowen JD, Kraft GH, Maravilla KR, et al
    Brain pathology of a patient 7years after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    J Neurol Sci. 2017;373:339-341.
    >> Share

  146. LANGESKOV-CHRISTENSEN M, Bisson EJ, Finlayson ML, Dalgas U, et al
    Potential pathophysiological pathways that can explain the positive effects of exercise on fatigue in multiple sclerosis: A scoping review.
    J Neurol Sci. 2017;373:307-320.
    >> Share

  147. FERREIRA KP, Oliveira SR, Kallaur AP, Kaimen-Maciel DR, et al
    Disease progression and oxidative stress are associated with higher serum ferritin levels in patients with multiple sclerosis.
    J Neurol Sci. 2017;373:236-241.
    >> Share

  148. KAWADA T
    Poor sleep and fatigue in patients with multiple sclerosis.
    J Neurol Sci. 2017;373:143.
    >> Share

  149. NOCITI V, Losavio FA, Gnoni V, Losurdo A, et al
    Response to the letter to the Editor for the manuscript "Sleep and Fatigue in Multiple Sclerosis: A questionnaire-based, cross-sectional, cohort study" by Tomoyuki Kawada.
    J Neurol Sci. 2017;373:142.
    >> Share

  150. ZAHOOR I, Haq E, Asimi R
    Multiple sclerosis in Kashmir: Where we stand.
    J Neurol Sci. 2017;373:129-133.
    >> Share

  151. TOGHI M, Taheri M, Arsang-Jang S, Ohadi M, et al
    SOCS gene family expression profile in the blood of multiple sclerosis patients.
    J Neurol Sci. 2017 Feb 9. pii: S0022-510X(17)30111.
    >> Share

    January 2017
  152. ALGAHTANI H, Marzouk Y, Algahtani R, Salman S, et al
    Autosomal Recessive Cerebellar Ataxia type 1 mimicking multiple sclerosis: A report of two siblings with a novel mutation in SYNE1 gene in a Saudi family.
    J Neurol Sci. 2017;372:97-100.
    >> Share

  153. MOTL RW, Sandroff BM, Pilutti LA, Klaren RE, et al
    Physical activity, sedentary behavior, and aerobic capacity in persons with multiple sclerosis.
    J Neurol Sci. 2017;372:342-346.
    >> Share

  154. BOESCHOTEN RE, Braamse AM, Beekman AT, Cuijpers P, et al
    Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2017;372:331-341.
    >> Share

  155. CAMEROTA F, Celletti C, Di Sipio E, De Fino C, et al
    Focal muscle vibration, an effective rehabilitative approach in severe gait impairment due to multiple sclerosis.
    J Neurol Sci. 2017;372:33-39.
    >> Share

  156. SABATINO JJ JR, Newsome SD
    Stiff person syndrome masquerading as multiple sclerosis.
    J Neurol Sci. 2017;372:297-299.
    >> Share

  157. CRNOSIJA L, Krbot Skoric M, Gabelic T, Adamec I, et al
    Vestibular evoked myogenic potentials and MRI in early multiple sclerosis: Validation of the VEMP score.
    J Neurol Sci. 2017;372:28-32.
    >> Share

  158. KISIC-TEPAVCEVIC D, Pekmezovic T, Trajkovic G, Stojsavljevic N, et al
    Corrigendum to "Sexual dysfunction in multiple sclerosis: A 6-year follow-up study" [J. Neurol. Sci. 358 (2015) 317-323].
    J Neurol Sci. 2017;372:201.
    >> Share

  159. CHALAH MA, Riachi N, Ahdab R, Mhalla A, et al
    Effects of left DLPFC versus right PPC tDCS on multiple sclerosis fatigue.
    J Neurol Sci. 2017;372:131-137.
    >> Share

  160. TAO C, Simpson S Jr, Taylor BV, van der Mei I, et al
    Association between human herpesvirus & human endogenous retrovirus and MS onset & progression.
    J Neurol Sci. 2017;372:239-249.
    >> Share

  161. BEH SC, Kildebeck E, Narayan R, Desena A, et al
    High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes.
    J Neurol Sci. 2017;372:187-195.
    >> Share

  162. TANIKAWA M, Nakahara J, Hata J, Suzuki S, et al
    q-Space Myelin Map imaging for longitudinal analysis of demyelination and remyelination in multiple sclerosis patients treated with fingolimod: A preliminary study.
    J Neurol Sci. 2017 Jan 5. pii: S0022-510X(17)30010.
    >> Share

  163. KIRA JI
    q-space Myelin Map imaging: A new imaging technique for treatment evaluation in multiple sclerosis.
    J Neurol Sci. 2017 Jan 4. pii: S0022-510X(17)30009.
    >> Share

    December 2016
  164. KOUDRIAVTSEVA T
    Body mass index and interferon-beta efficacy (and safety) in multiple sclerosis.
    J Neurol Sci. 2016;371:79-80.
    >> Share

    November 2016
  165. HERNANDEZ ME, Holtzer R, Chaparro G, Jean K, et al
    Brain activation changes during locomotion in middle-aged to older adults with multiple sclerosis.
    J Neurol Sci. 2016;370:277-283.
    >> Share

  166. SQUINTANI G, Donato F, Turri M, Deotto L, et al
    Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    J Neurol Sci. 2016;370:263-268.
    >> Share

  167. O'GORMAN CM, Broadley SA
    Smoking increases the risk of progression in multiple sclerosis: A cohort study in Queensland, Australia.
    J Neurol Sci. 2016;370:219-223.
    >> Share

  168. DE GIGLIO L, Upadhyay N, De Luca F, Prosperini L, et al
    Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis.
    J Neurol Sci. 2016;370:211-213.
    >> Share

  169. GAINDH D, Kavak KS, Teter B, Vaughn CB, et al
    Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.
    J Neurol Sci. 2016;370:13-17.
    >> Share

  170. GASPERINI C, Hupperts R, Lycke J, Short C, et al
    Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
    J Neurol Sci. 2016;370:123-131.
    >> Share

  171. HUHN K, Lammer R, Zimmermann H, Lammer A, et al
    Retinal imaging and axonal degeneration in later onset multiple sclerosis.
    J Neurol Sci. 2016;370:1-6.
    >> Share

    October 2016
  172. NOCITI V, Losavio FA, Gnoni V, Losurdo A, et al
    Sleep and fatigue in multiple sclerosis: A questionnaire-based, cross-sectional, cohort study.
    J Neurol Sci. 2016 Oct 27. pii: S0022-510X(16)30684.
    >> Share

  173. EFTEKHARIAN MM, Noroozi R, Sayad A, Sarrafzadeh S, et al
    RAR-related orphan receptor A (RORA): A new susceptibility gene for multiple sclerosis.
    J Neurol Sci. 2016;369:259-62.
    >> Share

  174. BERNARDINI LR, Zecca C, Clerici VT, Gobbi C, et al
    Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis.
    J Neurol Sci. 2016;369:139-40.
    >> Share

  175. YANG F, Estrada EF, Sanchez MC
    Vibration training improves disability status in multiple sclerosis: A pretest-posttest pilot study.
    J Neurol Sci. 2016;369:96-101.
    >> Share

  176. MANDEL JJ, Goethe EA, Patel AJ, Heck K, et al
    Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis.
    J Neurol Sci. 2016;369:51-2.
    >> Share

  177. TAWFIK TZ, Gad AH, Mehaney DA, El Nahrery E, et al
    Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
    J Neurol Sci. 2016;369:36-8.
    >> Share

    September 2016
  178. BRAMBILLA L, Rossi Sebastiano D, Aquino D, Torri Clerici V, et al
    Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
    J Neurol Sci. 2016;368:402-7.
    >> Share

  179. MESSMER UCCELLI M, Traversa S, Ponzio M
    A survey study comparing young adults with MS and healthy controls on self-esteem, self-efficacy, mood and quality of life.
    J Neurol Sci. 2016;368:369-73.
    >> Share

  180. SACCA F, Pane C, Carotenuto A, Massarelli M, et al
    The use of medical-grade cannabis in patients non-responders to Nabiximols.
    J Neurol Sci. 2016;368:349-51.
    >> Share

    June 2016
  181. KUUSISTO H, Vahvelainen T, Hamalainen P, Luukkaala T, et al
    Asymptomatic subjects differ less from their twin siblings with MS than from healthy controls in cognitive functioning. A Finnish Twin Cohort study.
    J Neurol Sci. 2016;365:50-3.
    >> Share

    April 2016
  182. TREMLETT H, Fadrosh DW, Faruqi AA, Hart J, et al
    Gut microbiota composition and relapse risk in pediatric MS: A pilot study.
    J Neurol Sci. 2016;363:153-7.
    >> Share

    March 2016
  183. HUDA S, Cavey A, Izat A, Mattison P, et al
    Nurse led telephone assessment of expanded disability status scale assessment in MS patients at high levels of disability.
    J Neurol Sci. 2016;362:66-8.
    >> Share

    January 2016
  184. MOORE P, Methley A, Pollard C, Mutch K, et al
    Cognitive and psychiatric comorbidities in neuromyelitis optica.
    J Neurol Sci. 2016;360:4-9.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016